The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
Open accessAbstract
BACKGROUND: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I-II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is unknown. METHODS: Advanced melanoma patients with accessible tumours had biopsy performed before the start of treatment with ADI-PEG20 and at the time of progression or relapse when amenable to determine whether argininosuccinate synthetase (ASS) expression in tumour was predictive of response to ADI-PEG20. RESULTS: Twenty-seven of thirty-eight patients treated had melanoma tumours assessable for ASS staining before treatment. Clinical benefit rate (CBR) and longer time to progression were associated with negative expression of tumour ASS. Only 1 of 10 patients with ASS-positive tumours (ASS+) had stable disease, whereas 4 of 17 (24%) had partial response and 5 had stable disease, when ASS expression was negative (ASS-), giving CBR rates of 52.9 vs 10%, P=0.041. Two responding patients with negative ASS expression before therapy had rebiopsy after tumour progression and the ASS expression became positive. The survival of ASS- patients receiving at least four doses at 320 IU m(-2) was significantly better than the ASS+ group at 26.5 vs 8.5 months, P=0.024. CONCLUSION: ADI-PEG20 is safe and the drug is only efficacious in melanoma patients whose tumour has negative ASS expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the use of arginine-catabolizing enzymes may not be an effective therapeutic strategy for all ASS1-deficient cancers, as some ADI-treated tumors have been found to re-express ASS1 (Feun et al., 2012; Long et al., 2013; Shen et al., 2003).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Feun et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sumiyoshi, K., Sato, N., Akagawa, S., Hirano, T., Koikawa, K., Horioka, K., Ozono, K., Fujiwara, K., Tanaka, M., & Sada, M. (2011) · Hepatogastroenterology · doi:10.5754/hge11125 · Cited by 2,450
Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycle
Husson, A., Brasse‐Lagnel, C., Fairand, A., Renouf, S., & Lavoinne, A. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03559.x · Cited by 335
Kim, R. H., Coates, J. M., Bowles, T. L., McNerney, G. P., Sutcliffe-Goulden, J., Jung, J. U., Gandour‐Edwards, R. F., Chuang, F. Y. S., Bold, R. J., & Kung, H.-J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3157 · Cited by 321
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2004) · Cancer · doi:10.1002/cncr.20057 · Cited by 317
Self-citationEnsor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315
Self-citationTapiero, H., Mathé, G., Couvreur, P., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00284-6 · Cited by 253
Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.120 · Cited by 250
Self-citationAscierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0933 · Cited by 238
Self-citationArginine Deprivation as a Targeted Therapy for Cancer
Feun, L. G., You, M., Wu, C., Kuo, M. T., Wangpaichitr, M., Spector, S. A., & Savaraj, N. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784246199 · Cited by 236
Self-citationSzlosarek, P. W., Klampatsa, A., Pallaska, A., Sheaff, M. T., Smith, P., Crook, T., Grimshaw, M. J., Steele, J. P. C., Rudd, R., Balkwill, F. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1101 · Cited by 181
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Feun L, Wu C, Clark M, Bomalask J, Holtsberg F, Wangpaichitr M, Robles C, Savaraj N (2004) Mechanism of antitumor effect of arginine deiminase-polyethylene (ADI-PEG20) and the possible mechanism of resistance in melanoma. Proc Am Assoc Can Res 45: 1054
Cited by
Sorted by citations
Items 101–113 of 113
You, M., Nguyen, D. M., Feun, L. G., Kuo, M. T., Wangpaichitr, M., Wu, C., & Savaraj, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812146-7.00025-1
Self-citationIfnar1 signaling breaks the hepatic urea cycle to regulate adaptive immunityPreprint
Lercher, A., Bhattacharya, A., Popa, A., Caldera, M., Schlapansky, M. F., Baazim, H., Májek, P., Brunner, J. S., Kosack, L., Vitko, D., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/762310
Amino Acid Metabolism in Acute Myeloid Leukemia
Mossuz, P., Mondet, J., & Rajesh, C. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/imcac.1.2021.4
Chung, S., Tam, S.-Y., Kim, C.-F., Chong, H.-C., Lee, L. M.-Y., & Leung, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1528620/v1
Старикова, Э. А., Mammedova, J. T., Ozhiganova, A., Burova, L. A., & Kudryavtsev, I. V. (2023) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093023050137
Старикова, Э. А., Mammedova, J. T., Ozhiganova, A., Burova, L. A., & Kudryavtsev, I. V. (2023) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s086981392309011x
SLC7A5 is required for citrulline-dependent growth in arginine limited conditionsPreprint
Dunlap, K. N., Bender, A., Bowles, A., Bott, A. J., Rutter, J. P., & Ducker, G. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.27.600869
Chessel, E., Khatir, W., Silva, A. C. B. S., Abbe, P., Béranger, G. E., Ding, Z., Passeron, T., Ben‐Sahra, I., Montaudié, H., Robert, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712479
Taki, F., Farhat, M. H., Atat, O. E., Al-Samman, S., Assaf, N., & Abi‐Habib, R. J. (2026) · Human Cell · doi:10.1007/s13577-026-01370-8
Plant virus-derived nanoparticles for the imaging and treatment of cancer
Gamper, C. (2019) · theses.fr (ABES) · doi:10.70675/844eefddz7e34z4b59z978bzda1d6c32d297
Biochemical characterization of mTORC1 regulation by glutamine metabolism
Bodineau, C. (2020) · theses.fr (ABES) · doi:10.70675/9d5aaabdz81bdz4118zb3edze237bdd8dee0
Abdelkhalek, M., El-Jawhari, Y., Shaheen, M., Saad, R., Sarieddine, M., El-Husseini, N., El‐Sibai, M., & Abi‐Habib, R. J. (2026) · CNS Oncology · doi:10.1080/20450907.2026.2666026
Metadata
- Authors
- Feun, L. G., Marini, A., Walker, G., Elgart, G., Moffat, F., Rodgers, S. E., Wu, C. J., You, M., Wangpaichitr, M., Kuo, M. T., Sisson, W., Jungbluth, A. A., Bomalaski, J., & Savaraj, N.
- Affiliations
- University of Miami (US)
- The University of Texas MD Anderson Cancer Center (US)
- Polaris Group (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Feun, L G
- Venue
- British Journal of Cancer
- Published
- 2012-04
- Volume
- 106
- Issue
- 9
- Pages
- 1481-1485
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC3341859
- OpenAlex
- W2033556277
- Cited by
- 113
- References
- 33
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 12 · 2022: 6 · 2021: 15 · 2020: 5 · 2019: 9 · 2018: 7 · 2017: 10 · 2016: 9 · 2015: 9 · 2014: 13 · 2013: 7 · 2012: 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA109578, R01CA152197)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- argininosuccinate synthetase, melanoma, pegylated arginine deiminase, predictive biomarkers, clinical benefit rate, time to progression, drug resistance, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Arginine, Argininosuccinate Synthase, Female, Humans, Hydrolases, Liver Neoplasms, Lung Neoplasms, Male, Melanoma, Middle Aged, Polyethylene Glycols, Skin Neoplasms, Survival Rate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
